👤 Qiu-Jing Chen

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
2981
Articles
1996
Name variants
Also published as: Ai-Qun Chen, Aiping Chen, Alex Chen, Alex F Chen, Alice P Chen, Alice Y Chen, Alice Ye A Chen, Allen Menglin Chen, Alon Chen, Alvin Chen, An Chen, Andrew Chen, Anqi Chen, Aoshuang Chen, Aozhou Chen, B Chen, B-S Chen, Baihua Chen, Ban Chen, Bang Chen, Bang-dang Chen, Bao-Bao Chen, Bao-Fu Chen, Bao-Sheng Chen, Bao-Ying Chen, Baofeng Chen, Baojiu Chen, Baolin Chen, Baosheng Chen, Baoxiang Chen, Beidong Chen, Beijian Chen, Ben-Kuen Chen, Benjamin Chen, Benjamin Jieming Chen, Benjamin P C Chen, Beth L Chen, Bihong T Chen, Bin Chen, Bing Chen, Bing-Bing Chen, Bing-Feng Chen, Bing-Huei Chen, Bingdi Chen, Bingqian Chen, Bingqing Chen, Bingyu Chen, Binlong Chen, Binzhen Chen, Bo Chen, Bo-Fang Chen, Bo-Jun Chen, Bo-Rui Chen, Bo-Sheng Chen, Bohe Chen, Bohong Chen, Bosong Chen, Bowang Chen, Bowei Chen, Bowen Chen, Boyu Chen, Brian Chen, C Chen, C Y Chen, C Z Chen, C-Y Chen, Cai-Long Chen, Caihong Chen, Can Chen, Cancan Chen, Canrong Chen, Canyu Chen, Caressa Chen, Carl Pc Chen, Carol Chen, Carol X-Q Chen, Catherine Qing Chen, Ceshi Chen, Chan Chen, Chang Chen, Chang-Lan Chen, Chang-Zheng Chen, Changjie Chen, Changya Chen, Changyan Chen, Chanjuan Chen, Chao Chen, Chao-Jung Chen, Chao-Wei Chen, Chaochao Chen, Chaojin Chen, Chaoli Chen, Chaoping Chen, Chaoqun Chen, Chaoran Chen, Chaoyi Chen, Chaoyue Chen, Chen Chen, Chen-Mei Chen, Chen-Sheng Chen, Chen-Yu Chen, Cheng Chen, Cheng-Fong Chen, Cheng-Sheng Chen, Cheng-Yi Chen, Cheng-Yu Chen, Chengchuan Chen, Chengchun Chen, Chengde Chen, Chengsheng Chen, Chengwei Chen, Chenyang Chen, Chi Chen, Chi-Chien Chen, Chi-Hua Chen, Chi-Long Chen, Chi-Yu Chen, Chi-Yuan Chen, Chi-Yun Chen, Chian-Feng Chen, Chider Chen, Chien-Hsiun Chen, Chien-Jen Chen, Chien-Lun Chen, Chien-Ting Chen, Chien-Yu Chen, Chih-Chieh Chen, Chih-Mei Chen, Chih-Ping Chen, Chih-Ta Chen, Chih-Wei Chen, Chih-Yi Chen, Chin-Chuan Chen, Ching Kit Chen, Ching-Hsuan Chen, Ching-Jung Chen, Ching-Wen Chen, Ching-Yi Chen, Ching-Yu Chen, Chiqi Chen, Chiung Mei Chen, Chiung-Mei Chen, Chixiang Chen, Chong Chen, Chongyang Chen, Christina Y Chen, Christina Yingxian Chen, Christopher S Chen, Chu Chen, Chu-Huang Chen, Chuanbing Chen, Chuannan Chen, Chuanzhi Chen, Chuck T Chen, Chueh-Tan Chen, Chujie Chen, Chun Chen, Chun-An Chen, Chun-Chi Chen, Chun-Fa Chen, Chun-Han Chen, Chun-Houh Chen, Chun-Wei Chen, Chun-Yuan Chen, Chung-Hao Chen, Chung-Hsing Chen, Chung-Hung Chen, Chung-Jen Chen, Chung-Yung Chen, Chunhai Chen, Chunhua Chen, Chunji Chen, Chunjie Chen, Chunlin Chen, Chunnuan Chen, Chunxiu Chen, Chuo Chen, Chuyu Chen, Cindi Chen, Constance Chen, Cuicui Chen, Cuie Chen, Cuilan Chen, Cuimin Chen, Cuncun Chen, D F Chen, D M Chen, D-F Chen, D. Chen, Dafang Chen, Daijie Chen, Daiwen Chen, Daiyu Chen, Dake Chen, Dali Chen, Dan Chen, Dan-Dan Chen, Dandan Chen, Danlei Chen, Danli Chen, Danmei Chen, Danna Chen, Danni Chen, Danxia Chen, Danxiang Chen, Danyang Chen, Danyu Chen, Daoyuan Chen, Dapeng Chen, Dawei Chen, Defang Chen, Dejuan Chen, Delong Chen, Denghui Chen, Dengpeng Chen, Deqian Chen, Dexi Chen, Dexiang Chen, Dexiong Chen, Deying Chen, Deyu Chen, Di Chen, Di-Long Chen, Dian Chen, Dianke Chen, Ding Chen, Diyun Chen, Dong Chen, Dong-Mei Chen, Dong-Yi Chen, Dongli Chen, Donglong Chen, Dongquan Chen, Dongrong Chen, Dongsheng Chen, Dongxue Chen, Dongyan Chen, Dongyin Chen, Du-Qun Chen, Duan-Yu Chen, Duo Chen, Duo-Xue Chen, Duoting Chen, E S Chen, Eleanor Y Chen, Elizabeth H Chen, Elizabeth S Chen, Elizabeth Suchi Chen, Emily Chen, En-Qiang Chen, Erbao Chen, Erfei Chen, Erqu Chen, Erzhen Chen, Everett H Chen, F Chen, F-K Chen, Fa Chen, Fa-Xi Chen, Fahui Chen, Fan Chen, Fang Chen, Fang-Pei Chen, Fang-Yu Chen, Fang-Zhi Chen, Fang-Zhou Chen, Fangfang Chen, Fangli Chen, Fangyan Chen, Fangyuan Chen, Faye H Chen, Fei Chen, Fei Xavier Chen, Feifan Chen, Feifeng Chen, Feilong Chen, Feixue Chen, Feiyang Chen, Feiyu Chen, Feiyue Chen, Feng Chen, Feng-Jung Chen, Feng-Ling Chen, Fenghua Chen, Fengju Chen, Fengling Chen, Fengming Chen, Fengrong Chen, Fengwu Chen, Fengyang Chen, Fred K Chen, Fu Chen, Fu-Shou Chen, Fumei Chen, Fusheng Chen, Fuxiang Chen, Gang Chen, Gao B Chen, Gao Chen, Gao-Feng Chen, Gaoyang Chen, Gaoyu Chen, Gaozhi Chen, Gary Chen, Gary K Chen, Ge Chen, Gen-Der Chen, Geng Chen, Gengsheng Chen, Ginny I Chen, Gong Chen, Gongbo Chen, Gonghai Chen, Gonglie Chen, Guan-Wei Chen, Guang Chen, Guang-Chao Chen, Guang-Yu Chen, Guangchun Chen, Guanghao Chen, Guanghong Chen, Guangjie Chen, Guangju Chen, Guangliang Chen, Guanglong Chen, Guangnan Chen, Guangping Chen, Guangquan Chen, Guangyao Chen, Guangyi Chen, Guangyong Chen, Guanjie Chen, Guanren Chen, Guanyu Chen, Guanzheng Chen, Gui Mei Chen, Gui-Hai Chen, Gui-Lai Chen, Guihao Chen, Guiqian Chen, Guiquan Chen, Guiying Chen, Guo Chen, Guo-Chong Chen, Guo-Jun Chen, Guo-Rong Chen, Guo-qing Chen, Guochao Chen, Guochong Chen, Guofang Chen, Guohong Chen, Guohua Chen, Guojun Chen, Guoliang Chen, Guopu Chen, Guoshun Chen, Guoxun Chen, Guozhong Chen, Guozhou Chen, H Chen, H Q Chen, H T Chen, Hai-Ning Chen, Haibing Chen, Haibo Chen, Haide Chen, Haifeng Chen, Haijiao Chen, Haimin Chen, Haiming Chen, Haining Chen, Haiqin Chen, Haiquan Chen, Haitao Chen, Haiyan Chen, Haiyang Chen, Haiyi Chen, Haiying Chen, Haiyu Chen, Haiyun Chen, Han Chen, Han-Bin Chen, Han-Chun Chen, Han-Hsiang Chen, Han-Min Chen, Hanbei Chen, Hang Chen, Hangang Chen, Hanjing Chen, Hanlin Chen, Hanqing Chen, Hanwen Chen, Hanxi Chen, Hanyong Chen, Hao Chen, Hao Yu Chen, Hao-Zhu Chen, Haobo Chen, Haodong Chen, Haojie Chen, Haoran Chen, Haotai Chen, Haotian Chen, Haoting Chen, Haoyun Chen, Haozhu Chen, Harn-Shen Chen, Haw-Wen Chen, He-Ping Chen, Hebing Chen, Hegang Chen, Hehe Chen, Hekai Chen, Heng Chen, Heng-Sheng Chen, Heng-Yu Chen, Hengsan Chen, Hengsheng Chen, Hengyu Chen, Heni Chen, Herbert Chen, Hetian Chen, Heye Chen, Hong Chen, Hong Yang Chen, Hong-Sheng Chen, Hongbin Chen, Hongbo Chen, Hongen Chen, Honghai Chen, Honghui Chen, Honglei Chen, Hongli Chen, Hongmei Chen, Hongmin Chen, Hongmou Chen, Hongqi Chen, Hongqiao Chen, Hongshan Chen, Hongxiang Chen, Hongxing Chen, Hongxu Chen, Hongyan Chen, Hongyu Chen, Hongyue Chen, Hongzhi Chen, Hou-Tsung Chen, Hou-Zao Chen, Hsi-Hsien Chen, Hsiang-Wen Chen, Hsiao-Jou Cortina Chen, Hsiao-Tan Chen, Hsiao-Wang Chen, Hsiao-Yun Chen, Hsin-Han Chen, Hsin-Hong Chen, Hsin-Hung Chen, Hsin-Yi Chen, Hsiu-Wen Chen, Hsuan-Yu Chen, Hsueh-Fen Chen, Hu Chen, Hua Chen, Hua-Pu Chen, Huachen Chen, Huafei Chen, Huaiyong Chen, Hualan Chen, Huali Chen, Hualin Chen, Huan Chen, Huan-Xin Chen, Huanchun Chen, Huang Chen, Huang-Pin Chen, Huangtao Chen, Huanhua Chen, Huanhuan Chen, Huanxiong Chen, Huaping Chen, Huapu Chen, Huaqiu Chen, Huatao Chen, Huaxin Chen, Huayu Chen, Huei-Rong Chen, Huei-Yan Chen, Huey-Miin Chen, Hui Chen, Hui Mei Chen, Hui-Chun Chen, Hui-Fen Chen, Hui-Jye Chen, Hui-Ru Chen, Hui-Wen Chen, Hui-Xiong Chen, Hui-Zhao Chen, Huichao Chen, Huijia Chen, Huijiao Chen, Huijie Chen, Huimei Chen, Huimin Chen, Huiqin Chen, Huiqun Chen, Huiru Chen, Huishan Chen, Huixi Chen, Huixian Chen, Huizhi Chen, Hung-Chang Chen, Hung-Chi Chen, Hung-Chun Chen, Hung-Po Chen, Hung-Sheng Chen, I-Chun Chen, I-M Chen, Ida Y-D Chen, Irwin Chen, Ivy Xiaoying Chen, J Chen, Jacinda Chen, Jack Chen, Jake Y Chen, Jason A Chen, Jeanne Chen, Jen-Hau Chen, Jen-Sue Chen, Jennifer F Chen, Jenny Chen, Jeremy J W Chen, Ji-ling Chen, Jia Chen, Jia Min Chen, Jia Wei Chen, Jia-De Chen, Jia-Feng Chen, Jia-Lin Chen, Jia-Mei Chen, Jia-Shun Chen, Jiabing Chen, Jiacai Chen, Jiacheng Chen, Jiade Chen, Jiahao Chen, Jiahua Chen, Jiahui Chen, Jiajia Chen, Jiajing Chen, Jiajun Chen, Jiakang Chen, Jiale Chen, Jiali Chen, Jialing Chen, Jiamiao Chen, Jiamin Chen, Jian Chen, Jian-Guo Chen, Jian-Hua Chen, Jian-Jun Chen, Jian-Kang Chen, Jian-Min Chen, Jian-Qiao Chen, Jian-Qing Chen, Jianan Chen, Jianfei Chen, Jiang Chen, Jiang Ye Chen, Jiang-hua Chen, Jianghua Chen, Jiangxia Chen, Jianhua Chen, Jianhui Chen, Jiani Chen, Jianjun Chen, Jiankui Chen, Jianlin Chen, Jianmin Chen, Jianping Chen, Jianshan Chen, Jiansu Chen, Jianxiong Chen, Jianzhong Chen, Jianzhou Chen, Jiao Chen, Jiao-Jiao Chen, Jiaohua Chen, Jiaping Chen, Jiaqi Chen, Jiaqing Chen, Jiaren Chen, Jiarou Chen, Jiawei Chen, Jiawen Chen, Jiaxin Chen, Jiaxu Chen, Jiaxuan Chen, Jiayao Chen, Jiaye Chen, Jiayi Chen, Jiayuan Chen, Jichong Chen, Jie Chen, Jie-Hua Chen, Jiejian Chen, Jiemei Chen, Jien-Jiun Chen, Jihai Chen, Jijun Chen, Jimei Chen, Jin Chen, Jin-An Chen, Jin-Ran Chen, Jin-Shuen Chen, Jin-Wu Chen, Jin-Xia Chen, Jina Chen, Jinbo Chen, Jindong Chen, Jing Chen, Jing-Hsien Chen, Jing-Wen Chen, Jing-Xian Chen, Jing-Yuan Chen, Jing-Zhou Chen, Jingde Chen, Jinghua Chen, Jingjing Chen, Jingli Chen, Jinglin Chen, Jingming Chen, Jingnan Chen, Jingqing Chen, Jingshen Chen, Jingteng Chen, Jinguo Chen, Jingxuan Chen, Jingyao Chen, Jingyi Chen, Jingyuan Chen, Jingzhao Chen, Jingzhou Chen, Jinhao Chen, Jinhuang Chen, Jinli Chen, Jinlun Chen, Jinquan Chen, Jinsong Chen, Jintian Chen, Jinxuan Chen, Jinyan Chen, Jinyong Chen, Jion Chen, Jiong Chen, Jiongyu Chen, Jishun Chen, Jiu-Chiuan Chen, Jiujiu Chen, Jiwei Chen, Jiyan Chen, Jiyuan Chen, Jonathan Chen, Joy J Chen, Juan Chen, Juan-Juan Chen, Juanjuan Chen, Juei-Suei Chen, Juhai Chen, Jui-Chang Chen, Jui-Yu Chen, Jun Chen, Jun-Long Chen, Junchen Chen, Junfei Chen, Jung-Sheng Chen, Junhong Chen, Junhui Chen, Junjie Chen, Junling Chen, Junmin Chen, Junming Chen, Junpan Chen, Junpeng Chen, Junqi Chen, Junqin Chen, Junsheng Chen, Junshi Chen, Junyang Chen, Junyi Chen, Junyu Chen, K C Chen, Kai Chen, Kai-En Chen, Kai-Ming Chen, Kai-Ting Chen, Kai-Yang Chen, Kaifu Chen, Kaijian Chen, Kailang Chen, Kaili Chen, Kaina Chen, Kaiquan Chen, Kan Chen, Kang Chen, Kang-Hua Chen, Kangyong Chen, Kangzhen Chen, Katharine Y Chen, Katherine C Chen, Ke Chen, Kecai Chen, Kehua Chen, Kehui Chen, Kelin Chen, Ken Chen, Kenneth L Chen, Keping Chen, Kequan Chen, Kevin Chen, Kewei Chen, Kexin Chen, Keyan Chen, Keyang Chen, Keying Chen, Keyu Chen, Keyuan Chen, Kuan-Jen Chen, Kuan-Ling Chen, Kuan-Ting Chen, Kuan-Yu Chen, Kuangyang Chen, Kuey Chu Chen, Kui Chen, Kun Chen, Kun-Chieh Chen, Kunmei Chen, Kunpeng Chen, L B Chen, L F Chen, Lan Chen, Lang Chen, Lankai Chen, Lanlan Chen, Lanmei Chen, Le Chen, Le Qi Chen, Lei Chen, Lei-Chin Chen, Lei-Lei Chen, Leijie Chen, Lena W Chen, Leqi Chen, Letian Chen, Lexia Chen, Li Chen, Li Jia Chen, Li-Chieh Chen, Li-Hsien Chen, Li-Hsin Chen, Li-Hua Chen, Li-Jhen Chen, Li-Juan Chen, Li-Mien Chen, Li-Nan Chen, Li-Tzong Chen, Li-Zhen Chen, Li-hong Chen, Lian Chen, Lianfeng Chen, Liang Chen, Liang-Kung Chen, Liangkai Chen, Liangsheng Chen, Liangwan Chen, Lianmin Chen, Liaobin Chen, Lichang Chen, Lichun Chen, Lidian Chen, Lie Chen, Liechun Chen, Lifang Chen, Lifen Chen, Lifeng Chen, Ligang Chen, Lihong Chen, Lihua Chen, Lijin Chen, Lijuan Chen, Lili Chen, Limei Chen, Limin Chen, Liming Chen, Lin Chen, Lina Chen, Linbo Chen, Ling Chen, Ling-Yan Chen, Lingfeng Chen, Lingjun Chen, Lingli Chen, Lingxia Chen, Lingxue Chen, Lingyi Chen, Linjie Chen, Linlin Chen, Linna Chen, Linxi Chen, Linyi Chen, Liping Chen, Liqiang Chen, Liugui Chen, Liujun Chen, Liutao Chen, Lixia Chen, Lixian Chen, Liyun Chen, Lizhen Chen, Lizhu Chen, Lo-Yun Chen, Long Chen, Long-Jiang Chen, Longqing Chen, Longyun Chen, Lu Chen, Lu Hua Chen, Lu-Biao Chen, Lu-Zhu Chen, Lulu Chen, Luming Chen, Luyi Chen, Luzhu Chen, M Chen, M L Chen, Man Chen, Man-Hua Chen, Mao Chen, Mao-Yuan Chen, Maochong Chen, Maorong Chen, Marcus Y Chen, Mark I-Cheng Chen, Max Jl Chen, Mechi Chen, Mei Chen, Mei-Chi Chen, Mei-Chih Chen, Mei-Hsiu Chen, Mei-Hua Chen, Mei-Jie Chen, Mei-Ling Chen, Mei-Ru Chen, Meilan Chen, Meilin Chen, Meiling Chen, Meimei Chen, Meiting Chen, Meiyang Chen, Meiyu Chen, Meizhen Chen, Meng Chen, Meng Xuan Chen, Meng-Lin Chen, Meng-Ping Chen, Mengdi Chen, Menglan Chen, Mengling Chen, Mengping Chen, Mengqing Chen, Mengting Chen, Mengxia Chen, Mengyan Chen, Mengying Chen, Mian-Mian Chen, Miao Chen, Miao-Der Chen, Miao-Hsueh Chen, Miao-Yu Chen, Miaomiao Chen, Miaoran Chen, Michael C Chen, Michelle Chen, Mien-Cheng Chen, Min Chen, Min-Hsuan Chen, Min-Hu Chen, Min-Jie Chen, Ming Chen, Ming-Fong Chen, Ming-Han Chen, Ming-Hong Chen, Ming-Huang Chen, Ming-Huei Chen, Ming-Yu Chen, Mingcong Chen, Mingfeng Chen, Minghong Chen, Minghua Chen, Minglang Chen, Mingling Chen, Mingmei Chen, Mingxia Chen, Mingxing Chen, Mingyang Chen, Mingyi Chen, Mingyue Chen, Minjian Chen, Minjiang Chen, Minjie Chen, Minyan Chen, Mo Chen, Mu-Hong Chen, Muh-Shy Chen, Mulan Chen, Mystie X Chen, Na Chen, Naifei Chen, Naisong Chen, Nan Chen, Ni Chen, Nian-Ping Chen, Ning Chen, Ning-Bo Chen, Ning-Hung Chen, Ning-Yuan Chen, Ningbo Chen, Ningning Chen, Nuan Chen, On Chen, Ou Chen, Ouyang Chen, P P Chen, Pan Chen, Paul Chih-Hsueh Chen, Pei Chen, Pei-Chen Chen, Pei-Chun Chen, Pei-Lung Chen, Pei-Yi Chen, Pei-Yin Chen, Pei-zhan Chen, Peihong Chen, Peipei Chen, Peiqin Chen, Peixian Chen, Peiyou Chen, Peiyu Chen, Peize Chen, Peizhan Chen, Peng Chen, Peng-Cheng Chen, Pengxiang Chen, Ping Chen, Ping-Chung Chen, Ping-Kun Chen, Pingguo Chen, Po-Han Chen, Po-Ju Chen, Po-Min Chen, Po-See Chen, Po-Sheng Chen, Po-Yu Chen, Qi Chen, Qi-An Chen, Qian Chen, Qianbo Chen, Qianfen Chen, Qiang Chen, Qiangpu Chen, Qiankun Chen, Qianling Chen, Qianming Chen, Qianping Chen, Qianqian Chen, Qianxue Chen, Qianyi Chen, Qianyu Chen, Qianyun Chen, Qianzhi Chen, Qiao Chen, Qiao-Yi Chen, Qiaoli Chen, Qiaoling Chen, Qichen Chen, Qifang Chen, Qihui Chen, Qili Chen, Qinfen Chen, Qing Chen, Qing-Hui Chen, Qing-Juan Chen, Qing-Wei Chen, Qingao Chen, Qingchao Chen, Qingchuan Chen, Qingguang Chen, Qinghao Chen, Qinghua Chen, Qingjiang Chen, Qingjie Chen, Qingliang Chen, Qingmei Chen, Qingqing Chen, Qingqiu Chen, Qingshi Chen, Qingxing Chen, Qingyang Chen, Qingyi Chen, Qinian Chen, Qinsheng Chen, Qinying Chen, Qiong Chen, Qiongyun Chen, Qiqi Chen, Qitong Chen, Qiu Jing Chen, Qiu-Sheng Chen, Qiuchi Chen, Qiuhong Chen, Qiujing Chen, Qiuli Chen, Qiuwen Chen, Qiuxia Chen, Qiuxiang Chen, Qiuxuan Chen, Qiuyun Chen, Qiwei Chen, Qixian Chen, Qu Chen, Quan Chen, Quanjiao Chen, Quanwei Chen, Qunxiang Chen, R Chen, Ran Chen, Ranyun Chen, Ray-Jade Chen, Ren-Hui Chen, Renjin Chen, Renwei Chen, Renyu Chen, Robert Chen, Roger Chen, Rong Chen, Rong-Hua Chen, Rongfang Chen, Rongfeng Chen, Rongrong Chen, Rongsheng Chen, Rongyuan Chen, Roufen Chen, Rouxi Chen, Ru Chen, Rucheng Chen, Ruey-Hwa Chen, Rui Chen, Rui-Fang Chen, Rui-Min Chen, Rui-Pei Chen, Rui-Zhen Chen, Ruiai Chen, Ruibing Chen, Ruijing Chen, Ruijuan Chen, Ruilin Chen, Ruimin Chen, Ruiming Chen, Ruiqi Chen, Ruisen Chen, Ruixiang Chen, Ruixue Chen, Ruiying Chen, Rujun Chen, Runfeng Chen, Runsen Chen, Runsheng Chen, Ruofan Chen, Ruohong Chen, Ruonan Chen, Ruoyan Chen, Ruoying Chen, S Chen, S N Chen, S Pl Chen, S-D Chen, Sai Chen, San-Yuan Chen, Sean Chen, Sen Chen, Shali Chen, Shan Chen, Shanchun Chen, Shang-Chih Chen, Shang-Hung Chen, Shangduo Chen, Shangsi Chen, Shangwu Chen, Shangzhong Chen, Shanshan Chen, Shanyuan Chen, Shao-Ke Chen, Shao-Peng Chen, Shao-Wei Chen, Shao-Yu Chen, Shao-long Chen, Shaofei Chen, Shaohong Chen, Shaohua Chen, Shaokang Chen, Shaokun Chen, Shaoliang Chen, Shaotao Chen, Shaoxing Chen, Shaoze Chen, Shasha Chen, She Chen, Shen Chen, Shen-Ming Chen, Sheng Chen, Sheng-Xi Chen, Sheng-Yi Chen, Shengdi Chen, Shenghui Chen, Shenglan Chen, Shengnan Chen, Shengpan Chen, Shengyu Chen, Shengzhi Chen, Shi Chen, Shi-Qing Chen, Shi-Sheng Chen, Shi-Yi Chen, Shi-You Chen, Shibo Chen, Shih-Jen Chen, Shih-Pin Chen, Shih-Yin Chen, Shih-Yu Chen, Shilan Chen, Shiming Chen, Shin-Wen Chen, Shin-Yu Chen, Shipeng Chen, Shiqian Chen, Shiqun Chen, Shirui Chen, Shiuhwei Chen, Shiwei Chen, Shixuan Chen, Shiyan Chen, Shiyao Chen, Shiyi Chen, Shiyu Chen, Shou-Tung Chen, Shoudeng Chen, Shoujun Chen, Shouzhen Chen, Shu Chen, Shu-Fen Chen, Shu-Gang Chen, Shu-Hua Chen, Shu-Jen Chen, Shuai Chen, Shuai-Bing Chen, Shuai-Ming Chen, Shuaijie Chen, Shuaijun Chen, Shuaiyin Chen, Shuaiyu Chen, Shuang Chen, Shuangfeng Chen, Shuanghui Chen, Shuchun Chen, Shuen-Ei Chen, Shufang Chen, Shufeng Chen, Shuhai Chen, Shuhong Chen, Shuhuang Chen, Shuhui Chen, Shujuan Chen, Shuliang Chen, Shuming Chen, Shunde Chen, Shuntai Chen, Shunyou Chen, Shuo Chen, Shuo-Bin Chen, Shuoni Chen, Shuqin Chen, Shuqiu Chen, Shuting Chen, Shuwen Chen, Shuyi Chen, Shuying Chen, Si Chen, Si-Ru Chen, Si-Yuan Chen, Si-Yue Chen, Si-guo Chen, Sien-Tsong Chen, Sifeng Chen, Sihui Chen, Sijia Chen, Sijuan Chen, Sili Chen, Silian Chen, Siping Chen, Siqi Chen, Siqin Chen, Sisi Chen, Siteng Chen, Siting Chen, Siyi Chen, Siyu Chen, Siyu S Chen, Siyuan Chen, Siyue Chen, Size Chen, Song Chen, Song-Mei Chen, Songfeng Chen, Suet N Chen, Suet Nee Chen, Sufang Chen, Suipeng Chen, Sulian Chen, Suming Chen, Sun Chen, Sung-Fang Chen, Suning Chen, Sunny Chen, Sy-Jou Chen, Syue-Ting Chen, Szu-Chi Chen, Szu-Chia Chen, Szu-Chieh Chen, Szu-Han Chen, Szu-Yun Chen, T Chen, Tai-Heng Chen, Tai-Tzung Chen, Tailai Chen, Tan-Huan Chen, Tan-Zhou Chen, Tania Chen, Tao Chen, Tian Chen, Tianfeng Chen, Tianhang Chen, Tianhong Chen, Tianhua Chen, Tianpeng Chen, Tianran Chen, Tianrui Chen, Tiantian Chen, Tianzhen Chen, Tielin Chen, Tien-Hsing Chen, Ting Chen, Ting-Huan Chen, Ting-Tao Chen, Ting-Ting Chen, Tingen Chen, Tingtao Chen, Tingting Chen, Tom Wei-Wu Chen, Tong Chen, Tongsheng Chen, Tse-Ching Chen, Tse-Wei Chen, TsungYen Chen, Tuantuan Chen, Tzu-An Chen, Tzu-Chieh Chen, Tzu-Ju Chen, Tzu-Ting Chen, Tzu-Yu Chen, Tzy-Yen Chen, Valerie Chen, W Chen, Wai Chen, Wan Jun Chen, Wan-Tzu Chen, Wan-Yan Chen, Wan-Yi Chen, Wanbiao Chen, Wanjia Chen, Wanjun Chen, Wanling Chen, Wantao Chen, Wanting Chen, Wanyin Chen, Wei Chen, Wei J Chen, Wei Ning Chen, Wei-Cheng Chen, Wei-Cong Chen, Wei-Fei Chen, Wei-Hao Chen, Wei-Hui Chen, Wei-Kai Chen, Wei-Kung Chen, Wei-Lun Chen, Wei-Min Chen, Wei-Peng Chen, Wei-Ting Chen, Wei-Wei Chen, Wei-Yu Chen, Wei-xian Chen, Weibo Chen, Weican Chen, Weichan Chen, Weicong Chen, Weihao Chen, Weihong Chen, Weihua Chen, Weijia Chen, Weijie Chen, Weili Chen, Weilun Chen, Weina Chen, Weineng Chen, Weiping Chen, Weiqin Chen, Weiqing Chen, Weirui Chen, Weisan Chen, Weitao Chen, Weitian Chen, Weiwei Chen, Weixian Chen, Weixin Chen, Weiyi Chen, Weiyong Chen, Wen Chen, Wen-Chau Chen, Wen-Jie Chen, Wen-Pin Chen, Wen-Qi Chen, Wen-Tsung Chen, Wen-Yi Chen, Wenbiao Chen, Wenbing Chen, Wenfan Chen, Wenfang Chen, Wenhao Chen, Wenhua Chen, Wenjie Chen, Wenjun Chen, Wenlong Chen, Wenqin Chen, Wensheng Chen, Wenshuo Chen, Wentao Chen, Wenting Chen, Wentong Chen, Wenwen Chen, Wenwu Chen, Wenxi Chen, Wenxing Chen, Wenxu Chen, Willian Tzu-Liang Chen, Wu-Jun Chen, Wu-Xian Chen, Wuyan Chen, X Chen, X R Chen, X Steven Chen, Xi Chen, Xia Chen, Xia-Fei Chen, Xiaguang Chen, Xiameng Chen, Xian Chen, Xian-Kai Chen, Xianbo Chen, Xiancheng Chen, Xianfeng Chen, Xiang Chen, Xiang-Bin Chen, Xiang-Mei Chen, XiangFan Chen, Xiangding Chen, Xiangjun Chen, Xiangli Chen, Xiangliu Chen, Xiangmei Chen, Xiangna Chen, Xiangning Chen, Xiangqiu Chen, Xiangyu Chen, Xiankai Chen, Xianmei Chen, Xianqiang Chen, Xianxiong Chen, Xianyue Chen, Xianze Chen, Xianzhen Chen, Xiao Chen, Xiao-Chen Chen, Xiao-Hui Chen, Xiao-Jun Chen, Xiao-Lin Chen, Xiao-Qing Chen, Xiao-Quan Chen, Xiao-Wei Chen, Xiao-Yang Chen, Xiao-Ying Chen, Xiao-chun Chen, Xiao-he Chen, Xiao-ping Chen, Xiaobin Chen, Xiaobo Chen, Xiaochang Chen, Xiaochun Chen, Xiaodong Chen, Xiaofang Chen, Xiaofen Chen, Xiaofeng Chen, Xiaohan Chen, Xiaohong Chen, Xiaohua Chen, Xiaohui Chen, Xiaojiang S Chen, Xiaojie Chen, Xiaojing Chen, Xiaojuan Chen, Xiaojun Chen, Xiaokai Chen, Xiaolan Chen, Xiaole L Chen, Xiaolei Chen, Xiaoli Chen, Xiaolin Chen, Xiaoling Chen, Xiaolong Chen, Xiaolu Chen, Xiaomeng Chen, Xiaomin Chen, Xiaona Chen, Xiaonan Chen, Xiaopeng Chen, Xiaoping Chen, Xiaoqian Chen, Xiaoqing Chen, Xiaorong Chen, Xiaoshan Chen, Xiaotao Chen, Xiaoting Chen, Xiaowan Chen, Xiaowei Chen, Xiaowen Chen, Xiaoxiang Chen, Xiaoxiao Chen, Xiaoyan Chen, Xiaoyang Chen, Xiaoyin Chen, Xiaoyong Chen, Xiaoyu Chen, Xiaoyuan Chen, Xiaoyun Chen, Xiatian Chen, Xihui Chen, Xijun Chen, Xikun Chen, Ximei Chen, Xin Chen, Xin-Jie Chen, Xin-Ming Chen, Xin-Qi Chen, Xinan Chen, Xing Chen, Xing-Lin Chen, Xing-Long Chen, Xing-Zhen Chen, Xingdong Chen, Xinghai Chen, Xingxing Chen, Xingyi Chen, Xingyong Chen, Xingyu Chen, Xinji Chen, Xinlin Chen, Xinpu Chen, Xinqiao Chen, Xinwei Chen, Xinyan Chen, Xinyang Chen, Xinyi Chen, Xinyu Chen, Xinyuan Chen, Xinyue Chen, Xinzhuo Chen, Xiong Chen, Xiqun Chen, Xiu Chen, Xiu-Juan Chen, Xiuhui Chen, Xiujuan Chen, Xiuli Chen, Xiuping Chen, Xiuxiu Chen, Xiuyan Chen, Xixi Chen, Xiyao Chen, Xiyu Chen, Xu Chen, Xuan Chen, Xuancai Chen, Xuanjing Chen, Xuanli Chen, Xuanmao Chen, Xuanwei Chen, Xuanxu Chen, Xuanyi Chen, Xue Chen, Xue-Mei Chen, Xue-Qing Chen, Xue-Xin Chen, Xue-Yan Chen, Xue-Ying Chen, XueShu Chen, Xuechun Chen, Xuefei Chen, Xuehua Chen, Xuejiao Chen, Xuejun Chen, Xueli Chen, Xueling Chen, Xuemei Chen, Xuemin Chen, Xueqin Chen, Xueqing Chen, Xuerong Chen, Xuesong Chen, Xueting Chen, Xueyan Chen, Xueying Chen, Xufeng Chen, Xuhui Chen, Xujia Chen, Xun Chen, Xuxiang Chen, Xuxin Chen, Xuzhuo Chen, Y Chen, Y D I Chen, Y Eugene Chen, Y M Chen, Y P Chen, Y S Chen, Y U Chen, Y-D I Chen, Y-D Ida Chen, Ya Chen, Ya-Chun Chen, Ya-Nan Chen, Ya-Peng Chen, Ya-Ting Chen, Ya-xi Chen, Yafang Chen, Yafei Chen, Yahong Chen, Yajie Chen, Yajing Chen, Yajun Chen, Yalan Chen, Yali Chen, Yan Chen, Yan Jie Chen, Yan Q Chen, Yan-Gui Chen, Yan-Jun Chen, Yan-Ming Chen, Yan-Qiong Chen, Yan-yan Chen, Yanan Chen, Yananlan Chen, Yanbin Chen, Yanfei Chen, Yanfen Chen, Yang Chen, Yang-Ching Chen, Yang-Yang Chen, Yangchao Chen, Yanghui Chen, Yangxin Chen, Yanhan Chen, Yanhua Chen, Yanjie Chen, Yanjing Chen, Yanli Chen, Yanlin Chen, Yanling Chen, Yanming Chen, Yann-Jang Chen, Yanping Chen, Yanqiu Chen, Yanrong Chen, Yanru Chen, Yanting Chen, Yanyan Chen, Yanyun Chen, Yanzhu Chen, Yanzi Chen, Yao Chen, Yao-Shen Chen, Yaodong Chen, Yaosheng Chen, Yaowu Chen, Yau-Hung Chen, Yaxi Chen, Yayun Chen, Yazhuo Chen, Ye Chen, Ye-Guang Chen, Yeh Chen, Yelin Chen, Yen-Chang Chen, Yen-Chen Chen, Yen-Cheng Chen, Yen-Ching Chen, Yen-Fu Chen, Yen-Hao Chen, Yen-Hsieh Chen, Yen-Jen Chen, Yen-Ju Chen, Yen-Lin Chen, Yen-Ling Chen, Yen-Ni Chen, Yen-Rong Chen, Yen-Teen Chen, Yewei Chen, Yi Chen, Yi Feng Chen, Yi-Bing Chen, Yi-Chun Chen, Yi-Chung Chen, Yi-Fei Chen, Yi-Guang Chen, Yi-Han Chen, Yi-Hau Chen, Yi-Heng Chen, Yi-Hong Chen, Yi-Hsuan Chen, Yi-Hui Chen, Yi-Jen Chen, Yi-Lin Chen, Yi-Ru Chen, Yi-Ting Chen, Yi-Wen Chen, Yi-Yung Chen, YiChung Chen, YiPing Chen, Yian Chen, Yibing Chen, Yibo Chen, Yidan Chen, Yiding Chen, Yidong Chen, Yiduo Chen, Yifa Chen, Yifan Chen, Yifang Chen, Yifei Chen, Yih-Chieh Chen, Yihao Chen, Yihong Chen, Yii-Der Chen, Yii-Der I Chen, Yii-Derr Chen, Yii-der Ida Chen, Yijiang Chen, Yijun Chen, Yike Chen, Yilan Chen, Yilei Chen, Yili Chen, Yilin Chen, Yiming Chen, Yin-Huai Chen, Ying Chen, Ying-Cheng Chen, Ying-Hsiang Chen, Ying-Jie Chen, Ying-Jung Chen, Ying-Lan Chen, Ying-Ying Chen, Yingchun Chen, Yingcong Chen, Yinghui Chen, Yingji Chen, Yingjie Chen, Yinglian Chen, Yingting Chen, Yingxi Chen, Yingying Chen, Yingyu Chen, Yinjuan Chen, Yintong Chen, Yinwei Chen, Yinzhu Chen, Yiru Chen, Yishan Chen, Yisheng Chen, Yitong Chen, Yixin Chen, Yiyin Chen, Yiyun Chen, Yizhi Chen, Yong Chen, Yong-Jun Chen, Yong-Ping Chen, Yong-Syuan Chen, Yong-Zhong Chen, YongPing Chen, Yongbin Chen, Yongfa Chen, Yongfang Chen, Yongheng Chen, Yonghui Chen, Yongke Chen, Yonglu Chen, Yongmei Chen, Yongming Chen, Yongning Chen, Yongqi Chen, Yongshen Chen, Yongshuo Chen, Yongxing Chen, Yongxun Chen, You-Ming Chen, You-Xin Chen, You-Yue Chen, Youhu Chen, Youjia Chen, Youmeng Chen, Youran Chen, Youwei Chen, Yu Chen, Yu-Bing Chen, Yu-Cheng Chen, Yu-Chi Chen, Yu-Chia Chen, Yu-Chuan Chen, Yu-Fan Chen, Yu-Fen Chen, Yu-Fu Chen, Yu-Gen Chen, Yu-Han Chen, Yu-Hui Chen, Yu-Ling Chen, Yu-Ming Chen, Yu-Pei Chen, Yu-San Chen, Yu-Si Chen, Yu-Ting Chen, Yu-Tung Chen, Yu-Xia Chen, Yu-Xin Chen, Yu-Yang Chen, Yu-Ying Chen, Yuan Chen, Yuan-Hua Chen, Yuan-Shen Chen, Yuan-Tsong Chen, Yuan-Yuan Chen, Yuan-Zhen Chen, Yuanbin Chen, Yuanhao Chen, Yuanjia Chen, Yuanjian Chen, Yuanli Chen, Yuanqi Chen, Yuanwei Chen, Yuanwen Chen, Yuanyu Chen, Yuanyuan Chen, Yubin Chen, Yucheng Chen, Yue Chen, Yue-Lai Chen, Yuebing Chen, Yueh-Peng Chen, Yuelei Chen, Yuewen Chen, Yuewu Chen, Yuexin Chen, Yuexuan Chen, Yufei Chen, Yufeng Chen, Yuh-Lien Chen, Yuh-Ling Chen, Yuh-Min Chen, Yuhan Chen, Yuhang Chen, Yuhao Chen, Yuhong Chen, Yuhui Chen, Yujie Chen, Yule Chen, Yuli Chen, Yulian Chen, Yulin Chen, Yuling Chen, Yulong Chen, Yulu Chen, Yumei Chen, Yun Chen, Yun-Ju Chen, Yun-Tzu Chen, Yun-Yu Chen, Yundai Chen, Yunfei Chen, Yunfeng Chen, Yung-Hsiang Chen, Yung-Wu Chen, Yunjia Chen, Yunlin Chen, Yunn-Yi Chen, Yunqin Chen, Yunshun Chen, Yunwei Chen, Yunyun Chen, Yunzhong Chen, Yunzhu Chen, Yupei Chen, Yupeng Chen, Yuping Chen, Yuqi Chen, Yuqin Chen, Yuqing Chen, Yuquan Chen, Yurong Chen, Yushan Chen, Yusheng Chen, Yusi Chen, Yuting Chen, Yutong Chen, Yuxi Chen, Yuxian Chen, Yuxiang Chen, Yuxin Chen, Yuxing Chen, Yuyan Chen, Yuyang Chen, Yuyao Chen, Z Chen, Zan Chen, Zaozao Chen, Ze-Hui Chen, Ze-Xu Chen, Zechuan Chen, Zemin Chen, Zetian Chen, Zexiao Chen, Zeyu Chen, Zhanfei Chen, Zhang-Liang Chen, Zhang-Yuan Chen, Zhangcheng Chen, Zhanghua Chen, Zhangliang Chen, Zhanglin Chen, Zhangxin Chen, Zhanjuan Chen, Zhao Chen, Zhao-Xia Chen, ZhaoHui Chen, Zhaojun Chen, Zhaoli Chen, Zhaolin Chen, Zhaoran Chen, Zhaowei Chen, Zhaoyao Chen, Zhe Chen, Zhe-Ling Chen, Zhe-Sheng Chen, Zhe-Yu Chen, Zhebin Chen, Zhehui Chen, Zhelin Chen, Zhen Bouman Chen, Zhen Chen, Zhen-Hua Chen, Zhen-Yu Chen, Zhencong Chen, Zhenfeng Chen, Zheng Chen, Zheng-Zhen Chen, Zhenghong Chen, Zhengjun Chen, Zhengling Chen, Zhengming Chen, Zhenguo Chen, Zhengwei Chen, Zhengzhi Chen, Zhenlei Chen, Zhenyi Chen, Zhenyue Chen, Zheping Chen, Zheren Chen, Zhesheng Chen, Zheyi Chen, Zhezhe Chen, Zhi Bin Chen, Zhi Chen, Zhi-Hao Chen, Zhi-bin Chen, Zhi-zhe Chen, Zhiang Chen, Zhichuan Chen, Zhifeng Chen, Zhigang Chen, Zhigeng Chen, Zhiguo Chen, Zhihai Chen, Zhihang Chen, Zhihao Chen, Zhiheng Chen, Zhihong Chen, Zhijian Chen, Zhijian J Chen, Zhijing Chen, Zhijun Chen, Zhimin Chen, Zhinan Chen, Zhiping Chen, Zhiqiang Chen, Zhiquan Chen, Zhishi Chen, Zhitao Chen, Zhiting Chen, Zhiwei Chen, Zhixin Chen, Zhixuan Chen, Zhixue Chen, Zhiyong Chen, Zhiyu Chen, Zhiyuan Chen, Zhiyun Chen, Zhizhong Chen, Zhong Chen, Zhongbo Chen, Zhonghua Chen, Zhongjian Chen, Zhongliang Chen, Zhongxiu Chen, Zhongzhu Chen, Zhou Chen, Zhouji Chen, Zhouliang Chen, Zhoulong Chen, Zhouqing Chen, Zhuchu Chen, Zhujun Chen, Zhuo Chen, Zhuo-Yuan Chen, ZhuoYu Chen, Zhuohui Chen, Zhuojia Chen, Zi-Jiang Chen, Zi-Qing Chen, Zi-Yang Chen, Zi-Yue Chen, Zi-Yun Chen, Zian Chen, Zifan Chen, Zihan Chen, Zihang Chen, Zihao Chen, Zihe Chen, Zihua Chen, Zijie Chen, Zike Chen, Zilin Chen, Zilong Chen, Ziming Chen, Zinan Chen, Ziqi Chen, Ziqing Chen, Zitao Chen, Zixi Chen, Zixin Chen, Zixuan Chen, Ziying Chen, Ziyuan Chen, Zoe Chen, Zongming E Chen, Zongnan Chen, Zongyou Chen, Zongzheng Chen, Zugen Chen, Zuolong Chen
articles
Cheng Wang, Na Qin, Meng Zhu +12 more · 2017 · Carcinogenesis · Oxford University Press · added 2026-04-24
Quantitative trait loci (QTLs) are widely used as instruments to infer causal risk factors of diseases based on the idea of mendelian randomization. Plasma metabolites can serve as risk factors of can Show more
Quantitative trait loci (QTLs) are widely used as instruments to infer causal risk factors of diseases based on the idea of mendelian randomization. Plasma metabolites can serve as risk factors of cancer, and the heritability of many circulating metabolites was high. We conducted a metabolome-wide association study (MWAS) to systematically investigate the effects of genetic variants on metabolites and lung cancer based on published genome-wide association study (GWASs) and metabolic-QTL (mQTL) study. Then we confirmed the results by subsequent genetic and metabolic validations and inferred the causal relationship between identified metabolites and lung cancer through genetic variant(s). We firstly identified six polyunsaturated fatty acids (PUFAs) represented by rs174548-linked haplotype were significantly associated with lung cancer risk in a Chinese GWAS (2311 cases and 3077 controls). Rs174548 was further confirmed to be associated with lung cancer in 13 821 Europeans and 18 471 Asians (ORmeta = 0.87, Pmeta = 1.76 × 10-15) and the effect was much stronger in females (Pinteraction = 6.00 × 10-4). We next validated rs174548-plasma PUFA association in 253 Chinese subjects (β = -0.57, P = 1.68 × 10-3). Rs174548 was also found associated with FADS1 (the major fatty acid desaturase of identified PUFAs) expression in liver tissues. Taken together, we found that rs174548 was associated with both PUFAs and lung cancer. Because rs174548 was the only mQTL variant of PUFAs reported by previous GWASs and explained a large proportion of heritability, we proposed that plasma PUFAs could be causally associated with lung cancer based on the idea of mendelian randomization. These findings provide a diet-related risk factor and may have important implications for prevention on lung cancer. Show less
no PDF DOI: 10.1093/carcin/bgx084
FADS1
Yang Dai, Ying Shen, Qing Run Li +11 more · 2017 · Journal of the American College of Cardiology · Elsevier · added 2026-04-24
Nonenzymatic glycation of apolipoproteins plays a role in the pathogenesis of the vascular complications of diabetes. This study investigated whether apolipoprotein (apo) A-IV was glycated in patients Show more
Nonenzymatic glycation of apolipoproteins plays a role in the pathogenesis of the vascular complications of diabetes. This study investigated whether apolipoprotein (apo) A-IV was glycated in patients with type 2 diabetes mellitus (T2DM) and whether apoA-IV glycation was related to coronary artery disease (CAD). The study also determined the biological effects of glycated apoA-IV. The authors consecutively enrolled 204 patients with T2DM without CAD (Group I), 515 patients with T2DM with CAD (Group II), and 176 healthy subjects (control group) in this study. ApoA-IV was precipitated from ultracentrifugally isolated high-density lipoprotein, and its glycation level was determined based on Western blotting densitometry (relative intensity of apoA-IV glycation). ApoA-IV NƐ-(carboxylmethyl) lysine (CML) modification sites were identified by mass spectrometry in 37 control subjects, 63 patients in Group I, and 138 patients in Group II. Saline or glycated apoA-IV (g-apoA-IV) generated by glyoxal culture was injected into apoE The relative intensity and the abundance of apoA-IV glycation were associated with the presence and severity of CAD in patients with T2DM (all p < 0.05). The experiments showed that g-apoA-IV induced proinflammatory reactions in vitro and promoted atherogenesis in apoE ApoA-IV glycation is associated with CAD severity in patients with T2DM, and g-apoA-IV induces atherogenesis through NR4A3 in apoE Show less
no PDF DOI: 10.1016/j.jacc.2017.08.053
APOA4
Yuan-Ke Liang, Hao-Yu Lin, Chun-Fa Chen +1 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
Chromobox (CBX) family proteins are canonical components in polycomb repressive complexes 1 (PRC1), with epigenetic regulatory function and transcriptionally repressing target genes via chromatin modi Show more
Chromobox (CBX) family proteins are canonical components in polycomb repressive complexes 1 (PRC1), with epigenetic regulatory function and transcriptionally repressing target genes via chromatin modification. A plethora of studies have highlighted the function specifications among CBX family members in various cancer, including lung cancer, colon cancer and breast cancer. Nevertheless, the functions and prognostic roles of distinct CBX family members in breast cancer (BC) remain elusive. In this study, we reported the prognostic values of CBX family members in patients with BC through analysis of a series of databases, including Show less
📄 PDF DOI: 10.18632/oncotarget.21325
CBX1
Ting-Huan Chen, Chen-Yu Chen, Hui-Chin Wen +4 more · 2017 · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · added 2026-04-24
Yes-associated protein (YAP) is a transcriptional coactivator in the Hippo pathway that regulates cell proliferation, differentiation, and apoptosis. The MEK5/ERK5 MAPK cascade is essential for the ea Show more
Yes-associated protein (YAP) is a transcriptional coactivator in the Hippo pathway that regulates cell proliferation, differentiation, and apoptosis. The MEK5/ERK5 MAPK cascade is essential for the early step of myogenesis. In this study, we generated C2C12 stable cell lines that expressed YAP (C2C12-YAP cells) and found that ERK5 and MEK5 were activated in C2C12-YAP cells compared with control C2C12 (C2C12-vector) cells. C2C12-YAP stable cells also differentiated into myotubes better than C2C12-vector cells, and expressed elevated levels of myogenin, a transcription factor that regulates myogenesis, as well as elevated levels of myosin heavy chain, a skeletal muscle marker. Western blot analysis revealed that Src and c-Abl (Abelson murine leukemia viral oncogene homolog 1) activation were enhanced in C2C12-YAP cells. Conversely, treatment of inhibitors of c-Abl, Src, or MEK5 inhibited activation of MEK5 and ERK5 and myogenesis of C2C12 myoblasts. Specific interactions between YAP and proteins in the ERK5 pathway, such as MEK kinase 3 (MEKK3) and ERK5, were illustrated by coimmunoprecipitation experiments. MEKK3 contains the PPGY motif (aa 178-181), which may interact with YAP. Site-directed mutagenesis experiments revealed that expression of MEKK3 Y181F mutant inhibited MEK5/ERK5 activation and myogenic differentiation. These results suggest that YAP promotes muscle differentiation by activating the Abl/Src/MEKK3/MEK5/ERK5 kinase cascade.-Chen, T.-H., Chen, C.-Y., Wen, H.-C., Chang, C.-C., Wang, H.-D., Chuu, C.-P., Chang, C.-H. YAP promotes myogenic differentiation Show less
no PDF DOI: 10.1096/fj.201601090R
MAP2K5
Vinit Shah, Michael E Lassman, Ying Chen +2 more · 2017 · Rapid communications in mass spectrometry : RCM · Wiley · added 2026-04-24
In quantitative analysis of protein biomarkers and therapeutic proteins by liquid chromatography/mass spectrometry (LC/MS), it is a preferred and well-established approach to digest with proteolytic e Show more
In quantitative analysis of protein biomarkers and therapeutic proteins by liquid chromatography/mass spectrometry (LC/MS), it is a preferred and well-established approach to digest with proteolytic enzymes to produce smaller peptide fragments which are more suitable for LC/MS analysis than the intact protein. In-solution digestion is one widely used method for protein digestion. Proteolytically resistant proteins often require digestion times that extend beyond normal working hours and prohibit same day analysis. We evaluated the performance of an immobilized enzyme reactor (IMER) to determine if this technology could reduce method development time, digestion time and increase throughput. We digested human plasma samples using a commercially available IMER, Flash Digest, and compared it to an in-solution digestion method for analysis of three different apolipoprotein biomarkers APOE, APOC2, and APOC3. The plasma digests were analyzed via LC/MS using electrospray ionization (ESI) and multiple reaction monitoring (MRM). Value assigned calibrators were selected over a relevant physiological concentration range for each protein of interest. Quality control samples (QCs) and 'unknown' human plasma samples were analyzed with both methods. Flash Digest significantly reduced digestion time for APOC3, the most proteolytically resistant of the three proteins, to 30 min compared with overnight used with in-solution digestion. The Flash Digest achieved comparable digestion efficiency with minimal method development and reduced sample preparation time. Both methods showed linearity over a physiologically relevant concentration range. Precision was evaluated and a percentage coefficient of variance (% CV) less than 8% was obtained during intra-day reproducibility evaluation for all three apolipoproteins with Flash Digest. Concentrations observed for QCs and unknown samples using Flash Digest were comparable to the in-solution method. An IMER such as Flash Digest may be a potential alternative to in-solution digestion to accelerate digestion of proteolytically resistant proteins in a quantitative proteomics experiments, reduce method development time and increase throughput. Copyright © 2016 John Wiley & Sons, Ltd. Show less
no PDF DOI: 10.1002/rcm.7778
APOC3
Yuan Li, Nan Sun, Zhiliang Lu +4 more · 2017 · Cancer letters · Elsevier · added 2026-04-24
Alternative splicing provides a major mechanism to generate protein diversity. Increasing evidence suggests a link of dysregulation of splicing associated with cancer. Genome-wide alternative splicing Show more
Alternative splicing provides a major mechanism to generate protein diversity. Increasing evidence suggests a link of dysregulation of splicing associated with cancer. Genome-wide alternative splicing profiling in lung cancer remains largely unstudied. We generated alternative splicing profiles in 491 lung adenocarcinoma (LUAD) and 471 lung squamous cell carcinoma (LUSC) patients in TCGA using RNA-seq data, prognostic models and splicing networks were built by integrated bioinformatics analysis. A total of 3691 and 2403 alternative splicing events were significantly associated with patient survival in LUAD and LUSC, respectively, including EGFR, CD44, PIK3C3, RRAS2, MAPKAP1 and FGFR2. The area under the curve of the receiver-operator characteristic curve for prognostic predictor in NSCLC was 0.817 at 2000 days of overall survival which were also over 0.8 in LUAD and LUSC, separately. Interestingly, splicing correlation networks uncovered opposite roles of splicing factors in LUAD and LUSC. We created prognostic predictors based on alternative splicing events with high performances for risk stratification in NSCLC patients and uncovered interesting splicing networks in LUAD and LUSC which could be underlying mechanisms. Show less
no PDF DOI: 10.1016/j.canlet.2017.02.016
PIK3C3
Min-Jie Lin, Wen Dai, Melanie J Scott +5 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
Apolipoprotein A5 (apoA5) has been implicated in the formation of hepatocyte lipid droplets, a histological hallmark of non-alcoholic fatty liver disease (NAFLD). Recent evidence demonstrated that liv Show more
Apolipoprotein A5 (apoA5) has been implicated in the formation of hepatocyte lipid droplets, a histological hallmark of non-alcoholic fatty liver disease (NAFLD). Recent evidence demonstrated that liver X receptor α (LXRα), a transcription factor involved in down-regulation of Show less
📄 PDF DOI: 10.18632/oncotarget.22163
APOA5
Jingwen Zhu, Ani Manichaikul, Yao Hu +9 more · 2017 · European journal of nutrition · Springer · added 2026-04-24
We aimed to characterize common genetic variants that influence saturated fatty acid concentrations in East Asians. Meta-analysis of genome-wide association studies for circulating SFAs was conducted Show more
We aimed to characterize common genetic variants that influence saturated fatty acid concentrations in East Asians. Meta-analysis of genome-wide association studies for circulating SFAs was conducted in two population-based cohorts comprising 3521 participants of Chinese ancestry. We identified two novel 14:0-associated loci at LMX1A (LIM homeobox transcription factor 1) and AMPD3 (AMP deaminase 3) (P = 5.08 × 10 To our knowledge, this is the first GWAS analysis to examine SFA concentrations in East Asian populations. Our findings provide novel evidence that genetic variations of several genes from multiple pathways are associated with SFA concentrations in human body. Show less
📄 PDF DOI: 10.1007/s00394-016-1193-1
FADS1
T Wang, X Ma, T Tang +13 more · 2017 · Nutrition & diabetes · Nature · added 2026-04-24
We aim to validate the effects of glucose-dependent insulinotropic polypeptide (GIP) on fat distribution and glucose metabolism in Han Chinese populations. We genotyped six tag single-nucleotide polym Show more
We aim to validate the effects of glucose-dependent insulinotropic polypeptide (GIP) on fat distribution and glucose metabolism in Han Chinese populations. We genotyped six tag single-nucleotide polymorphisms (SNPs) of GIP and four tag SNPs of glucose-dependent insulinotropic polypeptide receptor (GIPR) among 2884 community-based individuals from Han Chinese populations. Linear analysis was applied to test the associations of these variants with visceral fat area (VFA) and subcutaneous fat area (SFA) quantified by magnetic resonance imaging as well as glucose-related traits. We found that the C allele of rs4794008 of GIP tended to increase the VFA and the VFA/SFA ratio in all subjects (P=0.050 and P=0.054, respectively), and rs4794008 was associated with the VFA/SFA ratio in males (P=0.041) after adjusting for the BMI. The VFA-increasing allele of rs4794008 was not related to any glucose metabolism traits. However, rs9904288 of GIP was associated with the SFA in males as well as glucose-related traits in all subjects (P range, 0.004-0.049), and the GIPR variants displayed associations with both fat- and glucose-related traits. The results could provide the evidence that GIP might modulate visceral fat accumulation via incretin function or independent of incretin. Show less
📄 PDF DOI: 10.1038/nutd.2017.28
GIPR
Si-di Xie, Zi-Yang Chen, Hai Wang +6 more · 2017 · Nan fang yi ke da xue xue bao = Journal of Southern Medical University · added 2026-04-24
To investigate the role of microtubule-actin crosslinking factor 1 (MACF1) in the response of glioma cells to temozolomide (TMZ). TMZ was applied to a human gliomablastoma cell line (U87) and changes Show more
To investigate the role of microtubule-actin crosslinking factor 1 (MACF1) in the response of glioma cells to temozolomide (TMZ). TMZ was applied to a human gliomablastoma cell line (U87) and changes in the protein expression and cellular localization were determined with Western blot, RT-PCR, and immunofluorescence. The responses of the cells with MACF1 expression knockdown by RNA interference to TMZ were assessed. TMZ-induced effects on MACF1 expression were also assessed by immunohistochemistry in a nude mouse model bearing human glioblastoma xenografts. TMZ resulted in significantly increased MACF1 expression (by about 2 folds) and changes in its localization in the gliomablastoma cells both in vitro and in vivo (P<0.01). Knockdown of MACF1 reduced the proliferation (by 45%) of human glioma cell lines treated with TMZ (P<0.01). TMZ-induced changes in MACF1 expression was accompanied by cytoskeletal rearrangement. MACF1 may be a potential therapeutic target for glioblastoma. Show less
no PDF DOI: 10.3969/j.issn.1673-4254.2017.09.07
MACF1
Huiyuan Jing, Yanrong Zhou, Liurong Fang +5 more · 2017 · Frontiers in immunology · Frontiers · added 2026-04-24
DExD/H-box helicase 36 (DHX36) is known to be an ATP-dependent RNA helicase that unwinds the guanine-quadruplexes DNA or RNA, but emerging data suggest that it also functions as pattern recognition re Show more
DExD/H-box helicase 36 (DHX36) is known to be an ATP-dependent RNA helicase that unwinds the guanine-quadruplexes DNA or RNA, but emerging data suggest that it also functions as pattern recognition receptor in innate immunity. Porcine reproductive and respiratory syndrome virus (PRRSV) is an Show less
📄 PDF DOI: 10.3389/fimmu.2017.01365
DHX36
Pei-Wen Wang, Yu-Ching Hung, Tung-Ho Wu +3 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
Hepatic fibrosis may ultimately result in organ failure and death, a reality compounded by the fact that most drugs for liver fibrosis appear to be effective only if given as a prophylactic or early t Show more
Hepatic fibrosis may ultimately result in organ failure and death, a reality compounded by the fact that most drugs for liver fibrosis appear to be effective only if given as a prophylactic or early treatment. In a dimethylnitrosamine-induced liver fibrotic model, aspartate aminotransferase/alanine aminotransferase levels could not precisely distinguish the differences between the initial stage of liver fibrosis and normal control, whereas histological examination indicated that dimethylnitrosamine treatment for two weeks has resulted in hepatic fibrogenesis. Comprehensive proteomics identified 12 proteins mainly associated with the interleukin 6-stimulated inflammatory pathway. Coordinately, cytokine profiles showed that dimethylnitrosamine administration would stimulate various signaling pathways leading to liver fibrosis. Of note, apolipoprotein A4 in serum samples obtained from patients in the early stage of liver fibrosis were significantly increased compared to the healthy controls ( Show less
📄 PDF DOI: 10.18632/oncotarget.21627
APOA4
Yang An, Shuzhen Wang, Songlin Li +9 more · 2017 · BMC cancer · BioMed Central · added 2026-04-24
Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Expression profiling data were used to determin Show more
Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, clinicopathological characters and molecular pathways were analyzed in each subtype to prospect the clinical applications and progression mechanisms of ULMS. Two distinct molecular subtypes of ULMS were defined based on different gene expression signatures. Subtype I ULMS recapitulated low-grade ULMS, the gene expression pattern of which resembled normal smooth muscle cells, characterized by overexpression of smooth muscle function genes such as LMOD1, SLMAP, MYLK, MYH11. In contrast, subtype II ULMS recapitulated high-grade ULMS with higher tumor weight and invasion rate, and was characterized by overexpression of genes involved in the pathway of epithelial to mesenchymal transition and tumorigenesis, such as CDK6, MAPK13 and HOXA1. We identified two distinct molecular subtypes of ULMS responding differently to chemotherapy treatment. Our findings provide a better understanding of ULMS intrinsic molecular subtypes, and will potentially facilitate the development of subtype-specific diagnosis biomarkers and therapy strategies for these tumors. Show less
📄 PDF DOI: 10.1186/s12885-017-3568-y
LMOD1
Jifeng Zhang, Manabu Niimi, Dongshan Yang +16 more · 2017 · Arteriosclerosis, thrombosis, and vascular biology · added 2026-04-24
CETP (cholesteryl ester transfer protein) plays an important role in lipoprotein metabolism; however, whether inhibition of CETP activity can prevent cardiovascular disease remains controversial. We g Show more
CETP (cholesteryl ester transfer protein) plays an important role in lipoprotein metabolism; however, whether inhibition of CETP activity can prevent cardiovascular disease remains controversial. We generated CETP knockout (KO) rabbits by zinc finger nuclease gene editing and compared their susceptibility to cholesterol diet-induced atherosclerosis to that of wild-type (WT) rabbits. On a chow diet, KO rabbits showed higher plasma levels of high-density lipoprotein (HDL) cholesterol than WT controls, and HDL particles of KO rabbits were essentially rich in apolipoprotein AI and apolipoprotein E contents. When challenged with a cholesterol-rich diet for 18 weeks, KO rabbits not only had higher HDL cholesterol levels but also lower total cholesterol levels than WT rabbits. Analysis of plasma lipoproteins revealed that reduced plasma total cholesterol in KO rabbits was attributable to decreased apolipoprotein B-containing particles, while HDLs remained higher than that in WT rabbits. Both aortic and coronary atherosclerosis was significantly reduced in KO rabbits compared with WT rabbits. Apolipoprotein B-depleted plasma isolated from CETP KO rabbits showed significantly higher capacity for cholesterol efflux from macrophages than that from WT rabbits. Furthermore, HDLs isolated from CETP KO rabbits suppressed tumor necrosis factor-α-induced vascular cell adhesion molecule 1 and E-selectin expression in cultured endothelial cells. These results provide evidence that genetic ablation of CETP activity protects against cholesterol diet-induced atherosclerosis in rabbits. Show less
📄 PDF DOI: 10.1161/ATVBAHA.117.309114
CETP
Yanlei Ma, Jiping Yue, Yao Zhang +14 more · 2017 · Nature communications · Nature · added 2026-04-24
In the intestinal epithelium, the aberrant regulation of cell/cell junctions leads to intestinal barrier defects, which may promote the onset and enhance the severity of inflammatory bowel disease (IB Show more
In the intestinal epithelium, the aberrant regulation of cell/cell junctions leads to intestinal barrier defects, which may promote the onset and enhance the severity of inflammatory bowel disease (IBD). However, it remains unclear how the coordinated behaviour of cytoskeletal network may contribute to cell junctional dynamics. In this report, we identified ACF7, a crosslinker of microtubules and F-actin, as an essential player in this process. Loss of ACF7 leads to aberrant microtubule organization, tight junction stabilization and impaired wound closure in vitro. With the mouse genetics approach, we show that ablation of ACF7 inhibits intestinal wound healing and greatly increases susceptibility to experimental colitis in mice. ACF7 level is also correlated with development and progression of ulcerative colitis (UC) in human patients. Together, our results reveal an important molecular mechanism whereby coordinated cytoskeletal dynamics contributes to cell adhesion regulation during intestinal wound repair and the development of IBD. Show less
📄 PDF DOI: 10.1038/ncomms15375
MACF1
Yixia Wu, Lixin Zeng, Xueyan Chen +5 more · 2017 · Prostaglandins, leukotrienes, and essential fatty acids · Elsevier · added 2026-04-24
We investigated the association of single nucleotide polymorphisms (SNPs) in the fatty acid desaturase (FADS) gene cluster with coronary artery disease (CAD) in a case-control study and evaluated the Show more
We investigated the association of single nucleotide polymorphisms (SNPs) in the fatty acid desaturase (FADS) gene cluster with coronary artery disease (CAD) in a case-control study and evaluated the possible influence of genetic variation on total cholesterol (TC) and triglyceride concentrations in the controls. In total, 497 CAD patients and 495 unrelated controls were genotyped for eight SNPs in the FADS gene cluster, and the blood lipid levels of subjects were measured. Three genetic models, including codominant, dominant and recessive, were used to analyze the genotypic relationship with CAD and plasma lipid levels. Single locus genotypic analysis revealed that rs1000778 in FADS3 under a recessive model (AA vs. GG-GA) was significantly associated with CAD adjusted for risk factors. The rs1000778 minor allele AA was associated with a lower risk of CAD (OR =0.37, 95% CI: 0.15-0.89, P=0.025). In the control group, there were significant differences in TC concentrations under a recessive genetic model for rs174575 (C/G) in FADS2 and for rs174450 (A/C) and rs7115739 (G/T) in FADS3 (P=0.053, 0.016 and 0.018, respectively). The rs1000778-G variant in FADS3 may contribute to the susceptibility of CAD, but the result needs to be further confirmed because of small sample size in our study. Genetic variations in FADS2 and FADS3 influence TC concentration in the northern Chinese Han population. Show less
no PDF DOI: 10.1016/j.plefa.2017.01.014
FADS3
Xin-Hua Ye, Hong Chen, Qin Yu +1 more · 2017 · Medical science monitor : international medical journal of experimental and clinical research · added 2026-04-24
BACKGROUND Liver X receptor (LXR) is a nuclear receptor presenting in macrophages; it works indispensably in lipid metabolism control and also negatively regulates the expression of inflammatory genes Show more
BACKGROUND Liver X receptor (LXR) is a nuclear receptor presenting in macrophages; it works indispensably in lipid metabolism control and also negatively regulates the expression of inflammatory genes in macrophages. There are many LXR-related studies in adults with metabolic syndrome but rare reports in obese children with obstructive sleep apnea-hypopnea syndrome (OSAHS). The aim of this study was to investigate the expression of LXR, cholesterol ester transfer protein (CETP), and cyclooxygenase-2 (COX-2) genes in obese children with OSAHS compared with obese children without OSAHS and non-obese children. MATERIAL AND METHODS Sleep monitoring was conducted in 80 obese children with sleep disorders. Fasting morning blood samples from the 80 obese children and 51 normal children were collected and separated, so that macrophages were obtained after culture. Fluorescence quantitative real-time PCR (RT-PCR) was used to detect expression levels of the LXR, CETP, and COX-2 genes. RESULTS LXR, COX-2, and CETP levels in the OSAHS group were higher than those in the other two groups (P<0.05), and the LXR levels in the group of obese children without OSAHS were higher than those in control group (P<0.05). COX-2 expression in the group with moderate to severe OSAHS was higher than that in the group with mild OSAHS (P<0.05). Meanwhile, there were no significant differences in the LXR and CETP levels between the moderate to severe OSAHS group and the mild OSAHS group (P>0.05). CONCLUSIONS LXR gene expression was significantly increased in obese children with OSAHS. The severity of OSAHS was positively correlated with COX-2 levels. Show less
📄 PDF DOI: 10.12659/msm.900947
CETP
Fa Chen, Tao Lin, Lingjun Yan +8 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
The aim of this study was to investigate the independent and combined effects of fatty acid desaturase 1 (FADS1) gene polymorphism and fish consumption on oral cancer. A hospital-based case-control st Show more
The aim of this study was to investigate the independent and combined effects of fatty acid desaturase 1 (FADS1) gene polymorphism and fish consumption on oral cancer. A hospital-based case-control study was performed including 305 oral cancer patients and 579 cancer-free controls. The genotypes were determined by TaqMan genotyping assay. Non-conditional logistic regression model was used to assess the effects of FADS1 rs174549 polymorphism and fish intake. Subjects carrying A allele of rs174549 significantly reduced the risk of oral cancer (AA VS GG, OR: 0.65, 95% CI: 0.42-0.99; AA VS AG+GG, OR: 0.67, 95% CI: 0.46-0.98). Moreover, the statistically significant reverse associations were especially evident in men, smokers, alcohol drinkers and those age ≤ 60 years. Additionally, fish intake ≥7 times/week showed a 73% reduction in risk for oral cancer compared to those who ate fish less than 2 times/week (OR: 0.27, 95% CI: 0.18-0.42). Furthermore, a significant gene-diet multiplicative interaction was observed between FADS1 rs174549 polymorphism and fish intake for oral cancer (P=0.028). This preliminary study suggests that FADS1 rs174549 polymorphism and fish consumption may be protective factors for oral cancer, with a gene-diet multiplicative interaction. Functional studies with larger samples are required to confirm our findings. Show less
📄 PDF DOI: 10.18632/oncotarget.15069
FADS1
Jiayu Zhang, Maochong Chen, Jiawei Chen +4 more · 2017 · Bioscience reports · added 2026-04-24
Diabetic retinopathy (DR) is a complication of diabetes mellitus (DM) and is the leading cause of vision loss globally. However, the pathogenic mechanism and clinical therapy still needs further impro Show more
Diabetic retinopathy (DR) is a complication of diabetes mellitus (DM) and is the leading cause of vision loss globally. However, the pathogenic mechanism and clinical therapy still needs further improvement. The biologic significance of myocardial infarction associated transcript (MIAT) in DR remains unknown. Here, we aim to explore the mechanism between MIAT and DR, which is essential for RD. Streptozotocin (STZ) was used to induce DM mice and high glucose was used to stimulate cells. ChIP was used to detect the binding activity between nuclear factor κB (NF-κB) and the promoter of the MIAT gene, luciferase activity assay was used to detect the target-specific selectivity between Show less
no PDF DOI: 10.1042/BSR20170036
RMC1
Minzeng Sun, Lin Chen, Hui Liu +3 more · 2017 · Lipids in health and disease · BioMed Central · added 2026-04-24
The SstI polymorphism in the apolipoprotein 3 gene (apoC3) has been identified in many ethnic groups. In addition, the S2 allele of the SstI polymorphism is shown to be associated with increased plasm Show more
The SstI polymorphism in the apolipoprotein 3 gene (apoC3) has been identified in many ethnic groups. In addition, the S2 allele of the SstI polymorphism is shown to be associated with increased plasma triglyceride (TG) levels. Plasma apoCIII is an important atherogenic factor, which interrupts lipid metabolism and is positively associated with plasma TG levels. However, the existence of the SstI polymorphism in the Li ethnic group in China remains to be confirmed. The relationship between the S2 allele of the SstI polymorphism and plasma apoCIII or TG and their roles in atherosclerosis are also unknown. A cohort of 628 participants was recruited (316 atherosclerotic patients and 312 healthy controls) from both the Li and Han ethnic groups. Blood samples were obtained to evaluate the SstI polymorphism in the apoC3 and lipid profiles. Chi-squared and t-tests and multiple unconditional logistic regression were employed to analyze the genotypic and allelic frequencies and lipid profiles using SPSS version 20.0 software. The SstI polymorphism in the apoC3 was identified in the Li ethnic group. The S2 allele and plasma apoCIII and TG levels were associated with the development of atherosclerosis (P < 0.01, S2 allele and apoCIII; P < 0.05, TG) in the Li ethnic group. The S2 allele was associated with increased plasma apoCIII levels in the atherosclerotic group (P < 0.01), but with increased plasma apoCIII and TG levels in control group (both P < 0.01). In addition to the increases in the S2 allele frequency and plasma TG and apoCIII levels, atherosclerotic patients in the Li ethnic group also exhibited increased apoB, decreased HDL-C and apoAI and a lower apoAI:apoB ratio (all P < 0.01). Our results indicate that the S2 allele of the SstI polymorphism in the apoC3 gene is associated with plasma apoCIII levels in the Li population. In combination with unfavorable lipid profiles, this might contribute to susceptibility to atherosclerosis. Show less
📄 PDF DOI: 10.1186/s12944-017-0614-3
APOC3
Jian Ge, Qianxue Chen, Baohui Liu +3 more · 2017 · Cellular & molecular biology letters · BioMed Central · added 2026-04-24
Gliomas are commonly malignant tumors that arise in the human central nervous system and have a low overall five-year survival rate. Previous studies reported that several members of Rab GTPase family Show more
Gliomas are commonly malignant tumors that arise in the human central nervous system and have a low overall five-year survival rate. Previous studies reported that several members of Rab GTPase family are involved in the development of glioma, and abnormal expression of Rab small GTPases is known to cause aberrant tumor cell behavior. In this study, we characterized the roles of Rab21 (Rab GTPase 21), a member of Rab GTPase family, in glioma cells. The study involved downregulation of Rab21 in two glioma cell lines (T98G and U87) through transfection with specific-siRNA. Experiments using the MTT assay, cell cycle analysis, apoptosis assay, real-time PCR and western blot were performed to establish the expression levels of related genes. The results show that downregulation of Rab21 can significantly inhibit cell growth and remarkably induce cell apoptosis in T98G and U87 cell lines. Silencing Rab21 resulted in significantly increased expression of apoptosis-related proteins (caspase7, Bim and Bax) in glioma cells. We inferred that Rab21 silencing can induce apoptosis and inhibit proliferation in human glioma cells, indicating that Rab21 might act as an oncogene and serve as a novel target for glioma therapy. Show less
no PDF DOI: 10.1186/s11658-017-0062-0
RAB21
Yimin Zhu, DanDan Zhang, Dan Zhou +31 more · 2017 · Journal of cellular and molecular medicine · Blackwell Publishing · added 2026-04-24
Metabolic syndrome (MetS), a cluster of metabolic disturbances that increase the risk for cardiovascular disease and diabetes, was because of genetic susceptibility and environmental risk factors. To Show more
Metabolic syndrome (MetS), a cluster of metabolic disturbances that increase the risk for cardiovascular disease and diabetes, was because of genetic susceptibility and environmental risk factors. To identify the genetic variants associated with MetS and metabolic components, we conducted a genome-wide association study followed by replications in totally 12,720 participants from the north, north-eastern and eastern China. In combined analyses, independent of the top known signal at rs651821 on APOA5, we newly identified a secondary triglyceride-associated signal at rs180326 on BUD13 (P Show less
📄 PDF DOI: 10.1111/jcmm.13042
APOA5
Bei Zhao, Shouli Wang, Jinsong Chen +4 more · 2017 · Experimental and therapeutic medicine · added 2026-04-24
Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant cardiac disease, affecting 1 in 500 people. Myosin-binding protein C3 (
no PDF DOI: 10.3892/etm.2017.4089
MYBPC3
D J Luessen, H Sun, M M McGinnis +2 more · 2017 · Brain research · Elsevier · added 2026-04-24
Chronic alcohol exposure induces pronounced changes in GPCR-mediated G-protein signaling. Recent microarray and RNA-seq analyses suggest associations between alcohol abuse and the expression of genes Show more
Chronic alcohol exposure induces pronounced changes in GPCR-mediated G-protein signaling. Recent microarray and RNA-seq analyses suggest associations between alcohol abuse and the expression of genes involved in G-protein signaling. The activity of G-proteins (e.g. Gαi/o and Gαq) is negatively modulated by regulator of G-protein signaling (RGS) proteins which are implicated in drugs of abuse including alcohol. The present study used 7days of chronic intermittent ethanol exposure followed by 24h withdrawal (CIE) to investigate changes in mRNA and protein levels of G-protein subunit isoforms and RGS protein subtypes in rat prefrontal cortex, a region associated with cognitive deficit attributed to excessive alcohol drinking. We found that this ethanol paradigm induced differential expression of Gα subunits and RGS subtypes. For example, there were increased mRNA and protein levels of Gαi1/3 subunits and no changes in the expression of Gαs and Gαq subunits in ethanol-treated animals. Moreover, CIE increased the mRNA but not the protein levels of Gαo. Additionally, a modest increase in Gαi2 mRNA level by CIE was accompanied by a pronounced increase in its protein level. Interestingly, we found that CIE increased mRNA and protein levels of RGS2, RGS4, RGS7 and RGS19 but had no effect on the expression of RGS5, RGS6, RGS8, RGS12 or RGS17. Changes in the expression of Gα subunits and RGS subtypes could contribute to the functional alterations of certain GPCRs following chronic ethanol exposure. The present study suggests that RGS proteins may be potential new targets for intervention of alcohol abuse via modification of Gα-mediated GPCR function. Show less
no PDF DOI: 10.1016/j.brainres.2017.07.014
RGS17
Zhanfei Chen, Nanhong Tang, Xiaoqian Wang +1 more · 2017 · Journal of cellular and molecular medicine · Blackwell Publishing · added 2026-04-24
Carbamoyl phosphate synthase 1 (CPS1) is the rate-limiting enzyme in the first step of the urea cycle and an indispensable enzyme in the metabolism of human liver. However, CPS1 epigenetic regulation Show more
Carbamoyl phosphate synthase 1 (CPS1) is the rate-limiting enzyme in the first step of the urea cycle and an indispensable enzyme in the metabolism of human liver. However, CPS1 epigenetic regulation involves promoter analysis and the role of liver-enriched transcription factors (LETFs), which is not fully elucidated. In this work, the promoter region of hCPS1 gene was cloned, and its activity was investigated. An LETF, hepatocyte nuclear factor 3-beta (HNF3β), was found to promote the transcriptional expression of CPS1 in liver-derived cell lines. In addition, dual-luciferase reporter assay shows that the essential binding sites of the HNF3β may exist in the oligonucleotide -70 nt to +73 nt. Two putative binding sites are available for HNF3β. Mutation analysis results show that the binding site 2 of HNF3β was effective, and the transcriptional activity of CPS1 promoter significantly decreased after mutation. Electrophoretic mobile shift assay (EMSA) and ChIP assay confirmed that HNF3β can interact with the binding site in the CPS1 promoter region of -70 nt to +73 nt promoter region in vivo and in vitro to regulate the transcription of CPS1. Moreover, HNF3β overexpression enhanced the transcription of CPS1 and consequently improved the mRNA and protein levels of CPS1, whereas the knockdown of HNF3β showed the opposite effects. Finally, urea production in cells was measured, and ammonia detoxification improved significantly in cells after transfection with HNF3β. HNF3β plays a vital role in regulation of CPS1 gene and could promote the metabolism of ammonia by regulating CPS1 expression. Show less
📄 PDF DOI: 10.1111/jcmm.13123
CPS1
HPS3/TIMI55–REVEAL Collaborative Group, Louise Bowman, Jemma C Hopewell +9 more · 2017 · The New England journal of medicine · added 2026-04-24
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibitio Show more
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .). Show less
no PDF DOI: 10.1056/NEJMoa1706444
CETP
Rong-Quan He, Xiao-Jiao Li, Lu Liang +6 more · 2017 · BMC cancer · BioMed Central · added 2026-04-24
Non-small cell lung cancer (NSCLC) has led to the highest cancer-related mortality for decades. To enhance the efficiency of early diagnosis and therapy, more efforts are urgently needed to reveal the Show more
Non-small cell lung cancer (NSCLC) has led to the highest cancer-related mortality for decades. To enhance the efficiency of early diagnosis and therapy, more efforts are urgently needed to reveal the origins of NSCLC. In this study, we explored the effect of miR-542-5p in NSCLC with clinical samples and in vivo models and further explored the prospective function of miR-542-5p though bioinformatics methods. A total of 125 NSCLC tissue samples were collected, and the expression of miR-542-5p was detected by qRT-PCR. The relationship between miR-542-5p level and clinicopathological features was analyzed. The effect of miR-542-5p on survival time was also explored with K-M survival curves and Cox's regression. The effect of miR-542-5p on the tumorigenesis of NSCLC was verified with a chick chorioallantoic membrane (CAM) model. The potential target genes were predicted by bioinformatics tools, and relevant pathways were analyzed by GO and KEGG. Several hub genes were validated by Proteinatlas. The expression of miR-542-5p was down-regulated in NSCLC tissues, and consistent results were also found in the subgroups of adenocarcinoma and squamous cell carcinoma. Down-regulation of miR-542-5p was found to be connected with advanced TNM stage, vascular invasion, lymphatic metastasis and EGFR. Survival analyses showed that patients with lower miR-542-5p levels had markedly poorer prognosis. Both tumor growth and angiogenesis were significantly suppressed by miR-542-5p mimic in the CAM model. The potential 457 target genes of miR-542-5p were enriched in several key cancer-related pathways, such as morphine addiction and the cAMP signaling pathway from KEGG. Interestingly, six genes (GABBR1, PDE4B, PDE4C, ADCY6, ADCY1 and GIPR) from the cAMP signaling pathway were confirmed to be overexpressed in NSCLCs tissues. This evidence suggests that miR-542-5p is a potential tumor-suppressed miRNA in NSCLC, which has the potential to act as a diagnostic and therapeutic target of NSCLC. Show less
📄 PDF DOI: 10.1186/s12885-017-3646-1
GIPR
Meng-Chuan Huang, Wen-Tsan Chang, Hsin-Yu Chang +5 more · 2017 · International journal of environmental research and public health · MDPI · added 2026-04-24
Polyunsaturated fatty acids (PUFA) correlate with risk of dyslipidemia and cardiovascular diseases. Fatty acid desaturase (
📄 PDF DOI: 10.3390/ijerph14060572
FADS1
Lifang Hu, Yunyun Xiao, Zhipeng Xiong +9 more · 2017 · Seminars in cell & developmental biology · Elsevier · added 2026-04-24
Spectraplakins are a family of evolutionarily conserved gigantic proteins and play critical roles in many cytoskeleton-related processes. Microtubule actin crosslinking factor 1 (MACF1) is one of the Show more
Spectraplakins are a family of evolutionarily conserved gigantic proteins and play critical roles in many cytoskeleton-related processes. Microtubule actin crosslinking factor 1 (MACF1) is one of the most versatile spectraplakin with multiple isoforms. As a broadly expressed mammalian spectraplakin, MACF1 is important in maintaining normal functions of many tissues. The loss-of-function studies using knockout mouse models reveal the pivotal roles of MACF1 in embryo development, skin integrity maintenance, neural development, bone formation, and colonic paracellular permeability. Mutation in the human MACF1 gene causes a novel myopathy genetic disease. In addition, abnormal expression of MACF1 is associated with schizophrenia, Parkinson's disease, cancer and osteoporosis. This demonstrates the crucial roles of MACF1 in physiology and pathology. Here, we review the research advances of MACF1's roles in specific tissue and in human diseases, providing the perspectives of MACF1 for future studies. Show less
no PDF DOI: 10.1016/j.semcdb.2017.05.017
MACF1
Andrew R Wood, Anna Jonsson, Anne U Jackson +49 more · 2017 · Diabetes · added 2026-04-24
Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed Show more
Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed the largest genome-wide association study of first-phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 individuals without diabetes from 10 studies. We aimed to refine the mechanisms of 178 known associations between common variants and glycemic traits and identify new loci. Thirty type 2 diabetes or fasting glucose-raising alleles were associated with a measure of first-phase insulin secretion at Show less
no PDF DOI: 10.2337/db16-1452
VPS13C